MedTrace Logo

Peak Inspiratory Flow and Dry Powder Inhaler Performance in COPD

NCT04606394 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2023-05-08

Study results available
· View outcomes & findings →

Summary

The purpose of the study is to determine whether PIF is clinically important when using the Ellipta DPI device. In addition, the study will validate the best/most clinically appropriate way to perform a PIF maneuver, to determine the testing capabilities of the preferred PIF maneuver and to relate this PIF measurement to meaningful clinical outcomes in COPD patients

Conditions

Interventions

DRUG

Trelegy Ellipta 100/62.5/25Mcg Inh 30D

Administration of Trelegy in all patients

DRUG

Ventolin 90Mcg/Actuation Inhalation Aerosol

2 hours after the administration of Trelegy, administer Ventolin in all patients

Sponsors & Collaborators

  • GlaxoSmithKline

    collaborator INDUSTRY

  • Pulmonary Research Institute of Southeast Michigan

    lead OTHER

Principal Investigators

  • Gary T Ferguson, MD · Pulmonary Research Institute of Southeast Michigan

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
40 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-12-02
Primary Completion
2021-12-15
Completion
2021-12-15
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04606394 on ClinicalTrials.gov